<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918888</url>
  </required_header>
  <id_info>
    <org_study_id>ECS 1048/2021</org_study_id>
    <nct_id>NCT04918888</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccination in Oncologic Patients</brief_title>
  <acronym>VINCI</acronym>
  <official_title>SARS-CoV-2 Vaccination in Oncologic Patients: A Prospective, Explorative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Barmherzige Schwestern Linz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the vaccination willingness in oncologic patients over six months as well as&#xD;
      estimating the effects of radiotherapy/systemic anticancer treatment on the efficacy and&#xD;
      toxicity of currently approved SARS-CoV-2 vaccines&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients that present themselves newly at the outpatient-clinic of the Department of&#xD;
      Radiooncology at the Ordensklinikum Linz GmbH, Barmherzige Schwestern during a period of six&#xD;
      months are eligible for participation. After being informed about the study, the participants&#xD;
      answer a short structured interview regarding vaccination status and vaccination willingness.&#xD;
      Patients who already received one or two doses of SARS-CoV-2 vaccine are eligible for the&#xD;
      study's subpopulation 1, with the main focus of quantifying SARS-CoV-2 S binding antibody&#xD;
      titres after at least 35 days from initial vaccination. Patients who are to receive at least&#xD;
      one dose of vaccine during or up to six weeks after radiotherapy are eligible for&#xD;
      subpopulation 2, comprising serial measurements of SARS-CoV-2 S binding antibody titres&#xD;
      before and after vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of vaccination willingness</measure>
    <time_frame>once directly after enrollment</time_frame>
    <description>guided interview</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 antibody titre in already vaccinated patients</measure>
    <time_frame>&gt;= 35 days post first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 antibody titre in patients vaccinated during antineoplastic treatment</measure>
    <time_frame>baseline and 7, 14,21,28,35, 182 and 365 days post first dose</time_frame>
    <description>Development of antibody titre in patients who received the first or second dose of SARS-CoV-2 vaccine during radiotherapy, Longitudinal quantification of binding antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitive assessment of reasons to reject vaccination</measure>
    <time_frame>once directly after enrollment</time_frame>
    <description>guided interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitive assessment of comorbidities</measure>
    <time_frame>once after enrollment prior to vaccination</time_frame>
    <description>(in respect of the gravity of a SARS-CoV-2 infection corresponding to the WHO-grading), guided interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kind and dosage of accompanying systemic therapies</measure>
    <time_frame>once after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modalities and duration of the radiotherapy (irradiated region, single dose overall dose)</measure>
    <time_frame>once after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Previous SARS-CoV-2 infection (Rate of undetected cases via antibody detection, for known previous disease: evaluation of severity)</measure>
    <time_frame>once directly after enrollment and ev. at &gt;= 35 days after first dose</time_frame>
    <description>guided interview, conducted again at day 35 after the first dose for patients who receive radiotherapy during the first dose of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative assessment of local/systemic side effects of the SARS-CoV-2 vaccination</measure>
    <time_frame>35 days after vaccination</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of a symptomatic SARS-CoV-2 infection (duration, extent and severity)</measure>
    <time_frame>35 days after vaccination</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <condition>Oncologic Disorders</condition>
  <arm_group>
    <arm_group_label>Overall study population</arm_group_label>
    <description>All new oncologic patients of the outpatient-clinic of the department of radiooncology</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First dose received (Subpopulation 1)</arm_group_label>
    <description>Patients, who received one or two doses of SARS-CoV-2 vaccine prior to radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccination during therapy (Subpopulation 2)</arm_group_label>
    <description>Patients, who will receive at least one dose of SARS-CoV-2 vaccine during or up to 6 weeks after radiotherapy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        new patients of the department for radiooncology at the Ordensklinikum Barmherzige&#xD;
        Schwestern Linz&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Study population for the cross-sectional study (patients with previous SARS-CoV-2 infection&#xD;
        of previous vaccination, evaluation of willingness to get vaccinated:&#xD;
&#xD;
          -  Patients with solid tumors/haematooncologic diseases regardless of stage that seek&#xD;
             treatment in the outpatient clinic of the department of radiooncology from April to&#xD;
             September 2021 who will undergo active treatment.&#xD;
&#xD;
          -  Age: 18-120 years Patients that undergo radiotherapy, radio-chemotherapy,&#xD;
             radio-hormonotherapy or radio-immunotherapy during the investigation period.&#xD;
&#xD;
        Longitudinal study:&#xD;
&#xD;
          -  Patients that have not yet received SARS-CoV-2 vaccination, but are scheduled to get&#xD;
             the first dose during or up to six weeks after active therapy.&#xD;
&#xD;
          -  Age: 18-120 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of written consent&#xD;
&#xD;
          -  Patients, that are mentally or physically incapable of completing a questionnaire&#xD;
&#xD;
          -  Age: &lt; 18 years&#xD;
&#xD;
          -  A previous SARS-CoV-2 infection is no exclusion criteria!&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Geinitz, Univ.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ordensklinikum Linz GmbH, Barmherzige Schwestern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisabeth Silberberger, MSc</last_name>
    <phone>+437327677</phone>
    <phone_ext>6484</phone_ext>
    <email>elisabeth.silberberger@ordensklinikum.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Geinitz, Univ.-Prof.</last_name>
    <phone>+437327677</phone>
    <phone_ext>6938</phone_ext>
    <email>hans.geinitz@ordensklinikum.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH, Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <state>Ober√∂sterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Silberberger</last_name>
      <phone>07327677</phone>
      <phone_ext>6484</phone_ext>
      <email>elisabeth.silberberger@ordensklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Hans Geinitz, Univ.-Prof.</last_name>
      <phone>07327677</phone>
      <phone_ext>6973</phone_ext>
      <email>hans.geinitz@ordensklinikum.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Radiooncology, Ordensklinikum Linz GmbH Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Silberberger, MSC</last_name>
      <phone>+43 (732) 7677</phone>
      <phone_ext>6484</phone_ext>
      <email>elisabeth.silberberger@ordensklinikum.at</email>
    </contact>
    <contact_backup>
      <last_name>Hans Geinitz, Prim. Univ.-Prof. Dr.</last_name>
      <phone>+43 (732) 7677</phone>
      <phone_ext>6938</phone_ext>
      <email>hans.geinitz@ordensklinikum.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>SARS-CoV-2 vaccine</keyword>
  <keyword>immune response</keyword>
  <keyword>oncologic therapies</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>SARS-CoV-2 S binding antibodies</keyword>
  <keyword>vaccination willingness</keyword>
  <keyword>vaccination side effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

